Lyell Immunopharma is acquiring cell therapy startup ImmPact Bio for $30 million in cash and 37.5 million shares, with potential additional shares based on milestones. The company is streamlining its research focus on differentiated cellular immunotherapies for cancer, including the promising IMPT-314 therapy for blood cancers, while halting less successful projects. Following challenges since its IPO, Lyell aims for a turnaround with a financial runway extending into 2027.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
